Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 7297 participants.

Also called NCT05581303

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 7,297 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05581303
  • EudraCT 2022-501608-85
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Austria, Brazil, Bulgaria, China, Czechia, Estonia, Finland, France, Germany, Greece, Hong Kong SAR China, Hungary, Iceland, Italy, Japan, Mexico, Norway, Poland, South Korea, Spain, Sweden, Taiwan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05581303. Randomized; double masking; primary purpose treatment. Start 2022-12-14 (actual); primary completion 2028-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Placebo
Intervention (Drug)
Olpasiran
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct05581303
Content hash
a2ac9f8a13b1fd219b9de03f5b184712aa01624cc3bc8a96cea99715cd9b9c07